QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

NCT02384954 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

43

Enrollment

INDUSTRY

Sponsor class

Stopped Change in drug product development strategy.

Conditions

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: Rituximab
BIOLOGICAL: N-803

Sponsor

Altor BioScience